Back to today’s briefing

Story perspectives

FDA Issues New Warnings for ADHD Meds in Young Kids

7/1/2025

39 4

Summary

Story summary

The FDA has updated labeling for extended-release stimulants prescribed off-label for children under 6 with ADHD, highlighting risks of weight loss and increased adverse reactions. With around 7 million children in the U.S. affected by ADHD, these new warnings aim to ensure safer treatment options for the youngest patients.

1 of 1

Story summary

The FDA has updated labeling for extended-release stimulants prescribed off-label for children under 6 with ADHD, highlighting risks of weight loss and increased adverse reactions. With around 7 million children in the U.S. affected by ADHD, these new warnings aim to ensure safer treatment options for the youngest patients.